Glycopyrronium bromide
A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use
... Background: Glycopyrronium bromide has recently been approved as a once daily maintenance inhalation therapy for moderate to severe chronic obstructive pulmonary disease ...of glycopyrronium ...
8
Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
... outcomes. Glycopyrronium bromide (NVA237), a new LAMA, has been developed and received regulatory approval for management of COPD in a number of countries around the ...
13
Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
... Abstract: The goals of COPD therapy are to prevent and control symptoms, reduce the frequency and severity of exacerbations, and improve exercise tolerance. The triple combination therapy of inhaled corticosteroids ...
12
Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
... Inhaled glycopyrronium bromide is a long-acting muscarinic antagonist developed as a maintenance treatment for patients with ...that glycopyrronium produces rapid and sustained bronchodilation with ...
13
Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
... Breezhaler, glycopyrronium bromide can provide 24-hour bronchodilation with a rapid onset of action, faster than that of ...indacaterol, glycopyrronium bromide also has advantages for patient ...
10
A novel model-based approach for dose determination of glycopyrronium bromide in COPD
... muscle. Glycopyrronium bromide has a low oral bioavailability, is selective for M3 over muscarinic type 2 (M2) receptors, and equilibrates rapidly with M3 receptors ...
12
Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
... dipropionate/formoterol/glycopyrronium bromide fixed dose combination, which is the first treatment that comprises all the three drug classes, specifically tested for the prevention of moderate and severe ...
15
Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study
... antagonist glycopyrronium bromide (GB) is in development for chronic obstructive pulmonary disease (COPD), in combina- tion with beclometasone dipropionate and formoterol fumarate – a “fixed ...
14
Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease
... Glycopyrronium bromide is an effective bronchodilator in patients with COPD, and can be administered via dif- ferent delivery devices. This study evaluated the systemic bioavailability and bronchodilator ...
12
Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
... once-daily glycopyrronium bromide on exercise tolerance in patients with moderate to severe COPD (mean post- bronchodilator FEV 1 57% ...to glycopyrronium bromide 50 µ g once daily followed by ...
6
Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)
... Introduction: An extrafine formulation of the long-acting muscarinic antagonist, glycopyrronium bromide (GB), has been developed for delivery via the NEXThaler dry powder inhaler (DPI). This study assessed ...
11
DEVELOPMENT AND VALIDATION OF CHROMATOGRAPHIC AND SPECTROPHOTOMETRIC METHODS FOR SIMULTANEOUS ESTIMATION OF INDACATEROL MALEATE AND GLYCOPYRRONIUM BROMIDE IN PHARMACEUTICAL DOSAGE FORM AND THEIR COMPARISION USING STUDENT t-TEST
... Indacterol maleate and Glycopyrronium bromide combination is used for chronic obstructive pulmonary disease and newly introduced in market. It is necessary to develop suitable quality control methods for ...
13
Rapid simultaneous determination of indacaterol maleate and glycopyrronium bromide in inhaler capsules using a validated stability-indicating monolithic LC method
... Background: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. A combination of indacaterol maleate with glycopyrronium bromide has recently been approved as ...
8
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells
... the glycopyrronium/indacaterol combination com- pared with isolated airways treated with the monocom- ...by glycopyrronium, whereas indacaterol enhanced the cAMP levels by approximately three fold, ...
15
Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
... indacaterol, glycopyrronium, or both on PROs from COPD patients, which consisted of health status as assessed by the clinical COPD questionnaire and the level of dyspnea as measured by the modified Medical ...
6
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
... In the present GLOW6 (GLycopyrronium bromide in COPD airWays clinical study 6), we aimed to evaluate the efficacy and safety of the coadministration of a LABA (inda- caterol 150 [r] ...
14
A COMPARATIVE STUDY ON THE COMBINATION USE OF INDACATEROL WITH GLYCOPYRRONIUM AND FORMOTEROL WITH TIOTROPIUM IN COPD PATIENTS IN A TERTIARY CARE HOSPITAL
... This study was done to compare the effectiveness of Indacaterol with Glycopyrronium and Formoterol with Tiotropium in COPD patients. In the present study, the study subjects were COPD patients. The criteria for ...
9
COMPARISON OF PRECURARISATION WITH ROCURONIUM BROMIDE AND VECURONIUM BROMIDE FOR SUCCINYLCHOLINE HYDROCHLORIDE INDUCED POST OPERATIVE MYALGIA
... vecuronium bromide compared to 28.6% with rocuronium bromide may be considered clinically ...rocuronium bromide and d-tubocurarine group respectively at post operative 24 hours and 2 patients had ...
9
Butyltriphenylphosphonium bromide
... distances in the range 0.95–1.00 A Data collection: PROTEUM Bruker, 2002; cell refinement: SAINT-Plus Bruker, 2001; data reduction: SAINT-Plus; programs used to solve structure: SHELXS97[r] ...
7
Benzylethyldimethylammonium bromide
... benzyldimethylethylammonium bromide was performed to find out the influence of molecular geometry, and the length of the alkyl chain in particular, on the packing properties of the ammonium ...a bromide ...
9